Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis Q3 Revenues Grow 28 Percent

NEW YORK — IsoPlexis reported Wednesday morning that its Q3 2021 revenues were up 28 percent year over year.

For the three months ended Sept. 30, the Branford, Connecticut-based single-cell analysis company posted revenues of $4.2 million, up from $3.3 million in the year-ago period.

Product revenue was $3.9 million, up 30 percent from 3.0 million in Q3 2020, while service revenue was $303,000, up 19 percent from $254,000 in Q3 2020.

In October, IsoPlexis completed a $125 million initial public offering. The firm plans to use the proceeds for continued development and commercialization of its single-cell analysis platforms, which include its IsoLight, IsoSpark, and Duomics systems for the study of analytes including proteins, nucleic acids, and metabolites.

IsoPlexis' net loss attributable to common stockholders during the quarter was $23.6 million, or $10.66 per share, compared to $6.6 million, or $3.16 per share, in Q3 2020. The company used approximately 2.2 million shares to calculate per-share loss in the recently completed quarter compared to about 2.1 million shares in the year-ago period.

The company's R&D expenses were $4.7 million, up 88 percent from $2.5 million in Q3 2020. SG&A expenses were $17.2 million, up more than threefold from $5.5 million in the year-ago period.

IsoPlexis ended the quarter with $40.7 million in cash.

In Wednesday morning trading on the Nasdaq, IsoPlexis shares were up 4 percent to $15.17.